Beth Keyser
About Beth Keyser
Beth Keyser, age 56, is an independent director of NeurAxis, Inc. (NRXS) with more than 20 years of executive experience in population health. She holds an Executive Master of Science in Health Administration from the University of Alabama at Birmingham and has served on the NRXS board at least since 2024 and continues in 2025 .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Anthem, Inc. (BCBS of Indiana) | President | 2020–present | Population health leadership; multi-market solutions |
| Brighton Health Plan Solutions | President, Create | 2018–2020 | Built tailored employer health solutions |
| Sharecare, Inc. | SVP, International and Hawaii Markets | 2015–2020 | Led international/Hawaii market growth |
External Roles
| Organization | Role | Tenure |
|---|---|---|
| Public company directorships | None (NRXS directors are not directors in other reporting companies) | — |
| Anthem, Inc. (BCBS of Indiana) | President | 2020–present |
| Brighton Health Plan Solutions | President, Create | 2018–2020 |
| Sharecare, Inc. | SVP, International and Hawaii Markets | 2015–2020 |
Board Governance
- Independence: The board determined Beth Keyser is independent under SEC and NYSE American rules .
- Committees (2025): Audit Committee member; Compensation Committee member; Nominating & Corporate Governance Committee chair .
- Committee composition (2025) for context:
- Audit: Ferge (Chair), Watkins, Keyser; Ferge is the audit committee financial expert .
- Compensation: Aharon (Chair), Watkins, Keyser, Ferge .
- Nominating & Corporate Governance: Keyser (Chair), Watkins, Ferge .
- Years of service: Director listed in 2024 and 2025 proxies (at least since 2024) .
Fixed Compensation
| Metric | 2023 | 2024 |
|---|---|---|
| Fees Earned ($) | $23,836 | $60,000 |
| Committee Chair/Membership Fees | Not separately disclosed | Not separately disclosed |
| Meeting Fees | Not disclosed | Not disclosed |
| Total Cash ($) | $23,836 | $60,000 |
Performance Compensation
| Metric | 2023 | 2024 |
|---|---|---|
| Stock Awards Earned ($) | $19,863 | $50,000 |
| Award Vehicle per Plan | Equity awards available under 2022 Omnibus Plan (options, RSUs, PSUs, SARs); specific grant type for directors not disclosed | Equity awards available under 2022 Omnibus Plan (options, RSUs, PSUs, SARs); specific grant type for directors not disclosed |
Performance metric framework (plan-level, not director-specific):
- RSUs vest on service conditions; PSUs may pay out upon predetermined performance goals; specific performance metrics for director grants are not disclosed .
Other Directorships & Interlocks
| Category | Detail |
|---|---|
| Other public company boards | None (NRXS directors are not directors in other reporting companies) |
| Interlocks / shared directorships | None disclosed for Keyser |
| Related-party transactions | None involving Keyser disclosed; company maintains Audit Committee approval policy for related-party transactions |
Expertise & Qualifications
- More than 20 years in executive population health roles; experienced in complex, multi-segment market needs and solution design .
- Executive MS in Health Administration (UAB) .
- Current payer-side leadership (Anthem BCBS of Indiana), relevant to commercialization and reimbursement dynamics for medical technologies .
Equity Ownership
| Metric | 2024 | 2025 |
|---|---|---|
| Shares Beneficially Owned (#) | 0 (less than 1%) | 24,737 |
| Ownership % of Shares Outstanding | <1% | <1% |
| Voting Power % | <1% | <1% |
| Options/RSUs breakdown | Not disclosed | Not disclosed |
| Shares pledged | Not disclosed | Not disclosed |
Governance Assessment
- Strengths: Independent status; chairs Nominating & Corporate Governance; serves on Audit and Compensation Committees, supporting board effectiveness and oversight; audit committee has a designated financial expert (Ferge) alongside Keyser as a member .
- Alignment: Receives equity alongside cash retainers; 2024 director mix $60k cash and $50k equity indicates balanced pay structure for alignment, though specific grant type and vesting terms for directors are not disclosed .
- Ownership: Increased from no reported shares in 2024 to 24,737 shares in 2025, though still under 1%—a modest but positive signal of alignment .
- Conflicts/Red Flags: No related-party transactions disclosed for Keyser; board has a formal related-party review policy via the Audit Committee. No legal proceedings disclosed; directors are not on other reporting company boards, reducing interlock risk .